South America Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)     

Code: TIPRE00027715 | Pages: 119 | Industry: Medical Device | Date: Mar 2022 | Type: Regional

The SAM cervical cancer diagnostic testing market is expected to grow from US$ 366.73 million in 2021 to US$ 491.80 million by 2028; it is estimated to grow at a CAGR of 4.3% from 2021 to 2028.

The cervical cancer diagnosis test market players focus on launching new products to expand their geographic reach and enhance capacities to cater to a greater than existing customer base. In November 2021, Hologic, Inc. launched the Genius Digital Diagnostics System for cervical cancer screening. Next-generation screening systems combine deep earning-based artificial intelligence (AI) with the latest volumetric imaging technology to assess precancerous lesions and cervical cancer cells in women. Similarly, in 2019, BD’s COR PX/GX system was launched, which is available in centralized labs across region since 2019 to assist in high-volume processing and increase overall efficiency. Similarly, one popular government insurance program provides cover for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening. Such programs and developments and launches of new products are likely to bring new trends in the SAM cervical cancer diagnosis test market in the coming years, thereby supporting its growth.

 

In case of COVID-19, SAM is highly affected especially Brazil. The COVID-19 pandemic has placed unequalled demands on the health system. This led to delays in the initiation and completion of cancer treatment. The long-term health consequences can be assessed because of the delay in diagnosis and treatment for cervical cancer due to COVID-19. The COVID‐ 19 pandemic is a critical test for the already overburdened and underfunded public healthcare systems of SAM. It suffers from severe inequalities. With a vast population living in poverty, SAM continuously face widespread health problems due to overcrowding, limited sanitation, food insecurity, and unpredictable environmental conditions. Underfunded state‐run hospitals are the only source of medical care in the region. Brazil is in a critical situation due to COVID-19. Lack of resources is creating more challenges in the region, hampering the growth of the brain cancer diagnostics market. All these factors will restrict the distribution and adoption of diagnostics products and services which will restrict the market growth. Delays in diagnosis and treatment are likely to lead to more cervical cancer deaths as compared to COVID-19 mortality preclude among the patients with cervical cancer. Health systems must rearrange in terms of priority setting for provision of care, starting with prioritizing the treatment of patients with early-stage cervical cancer, increasing adoption of tele consultation, and reinforcing the role of primary care physicians in provision of cancer care. Hence, impact of pandemic will become moderated on the cervical cancer diagnostic testing market.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM cervical cancer diagnostic testing market. The SAM cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period. 

 

SAM Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)     

SAM Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)     

Get more information on this report :

 

SAM Cervical Cancer Diagnostic Testing Market Segmentation 

SAM Cervical Cancer Diagnostic Testing Market – By Type

  • PAP Testing
  • HPV Testing
  • Colposcopy
  • Cervical Biopsies
  • Cystoscopy
  • Others

SAM Cervical Cancer Diagnostic Testing Market – By Service Provider

  • Diagnostics and Research Laboratories
  • Hospitals and Clinics
  • Specialty Clinics
  • Home Care Services

SAM Cervical Cancer Diagnostic Testing Market, by Country

  • Brazil
  • Argentina  
  • Rest of SAM

SAM Cervical Cancer Diagnostic Testing Market - Companies Mentioned

  • Abbott
  • BD
  • Cooper Companies, Inc.
  • F. Hoffmann-La Roche Ltd.  
  • Femasys Inc.
  • Guided Therapeutics, Inc
  • Hologic, Inc.  
  • QIAGEN
  • Quest Diagnostics Incorporated   

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        SAM Cervical Cancer Diagnostic Testing Market – By Type

1.3.2        SAM Cervical Cancer Diagnostic Testing Market – By Service Provider

1.3.3        SAM Cervical Cancer Diagnostic Testing Market – By Country

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           SAM Cervical Cancer Diagnostic Testing Market – Market Landscape

4.1         Overview

4.2         SAM PEST Analysis

4.3         Experts Opinion

5.           SAM Cervical Cancer Diagnostic Testing Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increasing prevalence of cervical cancer

5.1.2        Rise in HPV Infections

5.2         Market Restraints

5.2.1        Lack of Awareness About Diagnosis and Treatment Methods

5.3         Market Opportunities

5.3.1        Development Opportunities in Emerging Countries

5.4         Future Trends

5.4.1        Development and Launch of Innovative Products

5.5         Impact Analysis

6.           Cervical Cancer Diagnostic Testing Market– SAM Analysis

6.1         SAM Cervical Cancer Diagnostic Testing Market Revenue Forecast and Analysis

7.           SAM Cervical Cancer Diagnostic Testing Market Analysis – By Type

7.1         Overview

7.2         SAM Cervical Cancer Diagnostic Testing Market, By Type, 2021 & 2028 (%)

7.3         PAP Testing

7.3.1        Overview

7.3.2        PAP Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

7.4         HPV Testing

7.4.1        Overview

7.4.2        HPV Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

7.5         Colposcopy

7.5.1        Overview

7.5.2        Colposcopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

7.6         Cervical Biopsies

7.6.1        Overview

7.6.2        Cervical Biopsies: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

7.7         Cystoscopy

7.7.1        Overview

7.7.2        Cystoscopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

7.8         Others

7.8.1        Overview

7.8.2        Others: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

8.           SAM Cervical Cancer Diagnostic Testing Market Analysis – By Service Provider

8.1         Overview

8.2         SAM Cervical Cancer Diagnostic Testing Market Share by Service Provider - 2021 & 2028 (%)

8.3         Diagnostics and Research Laboratories

8.3.1        Overview

8.3.2        Diagnostic Laboratories and Research Laboratories: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)

8.4         Hospitals and Clinics

8.4.1        Overview

8.4.2        Hospitals and Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)

8.5         Specialty Clinics

8.5.1        Overview

8.5.2        Specialty Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)

8.6         Home Care services

8.6.1        Overview

8.6.2        Home Care Services: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)

9.           SAM Cervical Cancer Diagnostic Testing Market – Country Analysis

9.1         SAM: Cervical Cancer Diagnostic Testing Market

9.1.1        Overview

9.1.2        SAM: Cervical Cancer Diagnostic Testing Market, by Country, 2021 & 2028 (%)

9.1.2.1          Brazil: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

9.1.2.2          Brazil: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

9.1.2.2.1          Brazil Cervical Cancer Diagnostic Testing Market, by Diagnostics Type– Revenue and Forecast to 2028 (USD Million)

9.1.2.2.2          Brazil Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (USD Million)

9.1.2.3          Argentina: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

9.1.2.3.1          Argentina: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

9.1.2.3.2          Argentina Cervical Cancer Diagnostic Testing Market, by Diagnostics Type– Revenue and Forecast to 2028 (USD Million)

9.1.2.3.3          Argentina Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (USD Million)

9.1.2.4          Rest of SAM: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

9.1.2.4.1          Rest of SAM: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

9.1.2.4.2          Rest of SAM Cervical Cancer Diagnostic Testing Market, by Type– Revenue and Forecast to 2028 (USD Million)

9.1.2.4.3          Rest of SAM Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (USD Million)

10.        Impact Of COVID-19 Pandemic on SAM Cervical Cancer Diagnostic Testing Market

10.1      SAM: Impact Assessment of COVID-19 Pandemic

11.        SAM Cervical Cancer Diagnostic Testing Market–Industry Landscape

11.1      Overview

11.2      Organic Developments

11.2.1     Overview

11.3      Inorganic Developments

11.3.1     Overview

12.        Company Profiles

12.1      F. Hoffmann-La Roche Ltd.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Abbott

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Quest Diagnostics Incorporated

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      QIAGEN

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      Hologic, Inc.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Femasys Inc.

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      Guided Therapeutics, Inc

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8      Cooper Companies, Inc.

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9      BD

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Products and Services

12.9.4     Financial Overview

12.9.5     SWOT Analysis

12.9.6     Key Developments

13.        Appendix

13.1      About The Insight Partners

13.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             SAM Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)

Table 2.             Brazil Cervical Cancer Diagnostic Testing Market, by Type– Revenue and Forecast to 2028 (USD Million)

Table 3.             Brazil Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (USD Million)

Table 4.             Argentina Cervical Cancer Diagnostic Testing Market, by Type– Revenue and Forecast to 2028 (USD Million)

Table 5.             Argentina Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (USD Million)

Table 6.             Rest of SAM Cervical Cancer Diagnostic Testing Market, by Type– Revenue and Forecast to 2028 (USD Million)

Table 7.             Rest of SAM Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (USD Million)

Table 8.             Organic Developments

Table 9.             Inorganic Developments

Table 10.          Glossary of Terms

 


LIST OF FIGURES

Figure 1.           SAM Cervical Cancer Diagnostic Testing Market Segmentation

Figure 2.           SAM Cervical Cancer Diagnostic Testing Market, By Country

Figure 3.           SAM Cervical Cancer Diagnostic Testing Market Overview

Figure 4.           PAP Testing Segment Held Largest Share of the Market in 2021

Figure 5.           Brazil is Expected to Show Remarkable Growth During the Forecast Period

Figure 6.           SAM: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Impact Analysis of Drivers and Restraints Pertaining to SAM Cervical Cancer Diagnostic Testing Market

Figure 9.           SAM Cervical Cancer Diagnostic Testing Market Forecast to 2028

Figure 10.        SAM Cervical Cancer Diagnostic Testing Market, by Type, 2021 & 2028 (%)

Figure 11.        SAM Pap Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12.        SAM HPV Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        SAM Colposcopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 14.        SAM Cervical Biopsies: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 15.        SAM Cystoscopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 16.        SAM Others: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 17.        SAM Cervical Cancer Diagnostic Testing Market Share by Service Provider - 2021 & 2028 (%)

Figure 18.        SAM Diagnostic Laboratories and Research Laboratories: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)

Figure 19.        SAM Hospitals and Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)

Figure 20.        SAM Specialty Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)

Figure 21.        SAM Home Care Services: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)

Figure 22.        SAM: Cervical Cancer Diagnostic Testing Market, by Key Country – Revenue (2021) (USD Million)

Figure 23.        SAM: Cervical Cancer Diagnostic Testing Market, by Country, 2021 & 2028 (%)

Figure 24.        Brazil: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

Figure 25.        Argentina: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

Figure 26.        Rest of SAM: Cervical Cancer Diagnostic Testing Market– Revenue and Forecast to 2028 (USD Million)

Figure 27.        Impact of COVID-19 Pandemic on Cervical cancer diagnostic testing Market in SAM Countries

  1. Abbott
  2. BD
  3. Cooper Companies, Inc.
  4. F. Hoffmann-La Roche Ltd.
  5. Femasys Inc.  
  6. Guided Therapeutics, Inc  
  7. Hologic, Inc.
  8. QIAGEN
  9. Quest Diagnostics Incorporated       
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000